Cue Biopharma

CUE · NASDAQ

$17.04+$0.96 (+5.97%)TodayMarket closed · Oct 20, 7:57 PM ET

Prev close $16.08

CUE analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $89.76 (+426.8% upside)

Low: $66.66
Now: $17.04
High: $120.75

Upgrades and downgrades

The latest rating actions, newest first

CUE analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
B. Riley Securities	Sep 18, 2026	Initiates	Buy	$83.00	47%

The case for and against

Updated Jan 11, 2025

Bull case

Cue Biopharma Inc. has demonstrated promising results in its clinical studies, particularly with the combination of CUE-101 and Keytruda achieving a robust overall response rate (ORR) of 46% in 1st-line recurrent/metastatic HPV+ head and neck squamous cell carcinoma, significantly outperforming Keytruda alone. The company's focus on advancing CUE-401 and the potential advantages over traditional cell therapies in treating autoimmune conditions also represents a strong strategic direction. The adjustments to the financial model reflect a positive outlook as Cue continues to refine its focus on autoimmune diseases and prepares for potential partnerships, aligning with increasing investor interest in innovative biopharmaceutical therapies.

Bear case

Cue Biopharma Inc. is experiencing a significant decrease in projected enterprise value, which has fallen from $432 million to $211 million, indicating potential concerns regarding the viability of its drug pipeline and overall financial health. A reduction in the 12-month price target from $8 to $3 reflects a reassessment of pipeline value in light of recent corporate restructuring and a delay in discounting timelines to mid-2025. These adjustments suggest that market confidence in the company's ability to deliver anticipated therapeutic outcomes has diminished, contributing to a negative outlook on its stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.